Healthcare Providers and Services
Company Overview of 23andMe, Inc.
23andMe, Inc. operates as a personal genetics company that provides ancestry-related genetic reports and uninterpreted raw genetic data. The company helps individuals understand their own genetic information through DNA analysis technologies and Web-based interactive tools. Its Personal Genome Service enables individuals to gain deeper insights into their ancestry and inherited traits. The company was founded in 2006 and is based in Mountain View, California.
1390 Shorebird Way
Mountain View, CA 94043
Founded in 2006
Key Executives for 23andMe, Inc.
Co-Founder, Chief Executive Officer and Director
Chief Science Officer and Head of Therapeutics
Chief Legal and Regulatory Officer
Compensation as of Fiscal Year 2015.
23andMe, Inc. Key Developments
23andMe, Inc. Appoints Scott Andress as Director of Product Design
Jul 14 15
23andMe, Inc. announced the appointment of Scott Andress as director of product design. Formerly with Yahoo and Apple, Andress will lead the design team responsible for creating unique and engaging customer experiences in the new realm of personal genetics pioneered by 23andMe. In addition to leading design for product experiences at 23andMe, Andress will focus on collaborating with product managers and engineers to drive design excellence for current and future 23andMe products. He and his team will work to create compelling products for both web and mobile applications.
23andMe, Inc. Launches Lupus Research Study in Collaboration with Pfizer Inc
May 5 15
23andMe, Inc. announced the launch of the Lupus Research Study in collaboration with Pfizer Inc. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort is also in collaboration with the Lupus Research Institute, and in concert with Lupus Awareness Month in May.
23andMe, Inc. Appoints Robert Gentleman as Vice President of Computational Biology
Apr 2 15
23andMe, Inc. announced the appointment of Robert Gentleman, Ph.D., as vice president of computational biology. Dr. Gentleman joins 23andMe to focus on the exploration of how the human genetic and trait data in the 23andMe database can be used to identify new therapies for disease. Most recently, Dr. Gentleman served as senior director of bioinformatics and computational biology at Genentech. In addition to broadly overseeing computational biology activities at the company, Dr. Gentleman will specifically focus on collaborating with Dr. Richard Scheller, 23andMe chief science officer and head of therapeutics. He will work with Dr. Scheller and others to help the newly formed therapeutics group utilize data analytics and theoretical models to identify trends and ultimately advance the drug research and discovery process.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 18, 2015
Most Searched Private Companies
Sponsored Financial Commentaries